| 000 | 01385nam\a2200313\a\4500 | ||
|---|---|---|---|
| 001 | 57920 | ||
| 005 | 20260728140918.0 | ||
| 008 | 260728s2017 enk b 001 0 eng | ||
| 020 |
_a9781119289746 _qpbk. |
||
| 020 | _z9781119289753 (Adobe PDF) | ||
| 020 | _z9781119289784 (epub) | ||
| 040 |
_aDNLM/DLC _cDLC _erda _dBD-DhIUB |
||
| 082 | 0 | 0 |
_a615.7042 _223 _bW1871i |
| 100 | 1 |
_aWaller, Patrick, _d1957 January 30- _eauthor. |
|
| 245 | 1 | 3 |
_aAn introduction to pharmacovigilance / _cPatrick Waller, Mira Harrison-Woolrych. |
| 250 | _a2nd edition. | ||
| 260 |
_aUK: _bJohn Wiley and Sons Ltd., _c2017 |
||
| 300 |
_a170p. ; _c24cm. |
||
| 504 | _aIncludes bibliographical references and index. | ||
| 505 | 0 | _aWhat is pharmacovigilance and how has it developed? -- Basic concepts -- Types and sources of data -- The process of pharmacovigilance -- Regulatory aspects of pharmacovigilance -- International collaboration -- Clinical aspects of adverse drug reactions -- Ethical and societal considerations -- Future directions -- Learning more about pharmacovigilance. | |
| 526 |
_aPHR _bphr _lPHAR |
||
| 541 | _aOmni concept | ||
| 650 | 1 | 2 | _aPharmacovigilance |
| 650 | 2 | 2 |
_aDrug Monitoring _xmethods |
| 650 | 2 | 2 | _aDrug-Related Side Effects and Adverse Reactions |
| 650 | 2 | 2 |
_aPharmaceutical Preparations _xstandards |
| 700 | 1 |
_aHarrison-Woolrych, Mira, _eauthor. |
|
| 942 |
_2ddc _cBK |
||
| 999 |
_c57920 _d58094 |
||